COMP <GO>
GH vs UNH // 10Y YIELD & FRED MACRO BETA
Guardant Health Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GH 5
— UNH 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: GH
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
macro-sensitivity
0.87
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 88.57% | -24.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 11.47% | -28.87 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 6.48% | -7.42 | UNH | /fcf-yield <GO> |
| Operating Margin | -44.50% | 4.82% | -49.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 3.14% | -45.54 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 6.46% | +26.44 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 3.12 | +2.32 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.74% | -0.24 | GH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 56.0 | +1.20 | GH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.87 | 0.33 | +0.54 | GH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 17.1x | +1.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $364.66B | -$339.79B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | UNH REV | GH GROSS % | UNH GROSS % | GH FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $447.57B | 64.5% | 88.7% | -$233.1M | $16.07B |
| FY 2024 | $739.0M | $400.28B | 60.8% | 88.3% | -$274.9M | $20.70B |
| FY 2023 | $563.9M | $371.62B | 44.0% | 89.6% | -$350.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
UNH // BETA 0.33